Advertisement

Strategies for optimizing treatment with efalizumab in moderate to severe psoriasis

  • Kim A. PappEmail author
  • Vincent Ho
  • Richard Langley
  • Charles Lynde
  • Yves Poulin
  • Neil Shear
  • John Toole
  • Catherine Zip
Article

Abstract

With the advent of biological therapies for the treatment of plaque psoriasis, guidance on the usage of these new agents has become necessary. One such agent, efalizumab, a humanized recombinant monoclonal IgG1 antibody developed to target T-cell-mediated inflammation, provides rapid and sustained efficacy for many psoriasis patients. This article explores the pretreatment, initiation, and treatment phases with efalizumab therapy. In the pretreatment phase, physicians need to assess patients’ disease state and educate them about the course of efalizumab treatment. Prior to initiation, physicians need to establish stable disease, ensure an adequate transition or washout of any prior psoriasis therapeutics, and obtain baseline platelet counts. After initiating treatment, both physician and patient must participate in disease monitoring. Patients responding favourably may receive continuous treatment. Those who do not respond to the drug or who experience adverse events should be managed appropriately in order to continue therapy or be transitioned onto another agent. A growing body of clinical evidence, as well as experience from clinical investigators, has provided much insight into the management strategies for patients undergoing treatment with efalizumab.

Keywords

continuous efalizumab long-term psoriasis 

Notes

Acknowledgement

This work was supported in part by an educational grant from Serono Canada Inc.

References

  1. 1.
    Ashcroft DM, Li Wan Po A, Griffiths CE. Therapeutic strategies for psoriasis J Clin Pharm Ther 2000; 25:1–10PubMedCrossRefGoogle Scholar
  2. 2.
    Krueger G, Koo J, Lebwohl M, et al. The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey. Arch Dermatol 2001; 137:280–284PubMedGoogle Scholar
  3. 3.
    Singri P, West DP, Gordon KB. Biologic therapy for psoriasis: the new therapeutic frontier. Arch Dermatol 2002; 138:657–663PubMedCrossRefGoogle Scholar
  4. 4.
    Werther WA, Gonzalez TN, O’Connor SJ, et al. Humanization of an anti-lymphocyte function-associated antigen (LFA)-1 monoclonal antibody and reengineering of the humanized antibody for binding to rhesus LFA-1. J Immunol 1996; 157:4986–4995PubMedGoogle Scholar
  5. 5.
    Shear NH, Langley RG, Ho V. Efalizumab, a reversible T-cell modulator for psoriasis. J Cutan Med Surg 2005; This supplementGoogle Scholar
  6. 6.
    Gordon K, Siegfried E, Carey W, et al. Impact of 24 weeks of continuous efalizumab therapy on patient-reported outcomes in patients with moderate to severe plaque psoriasis. Presented at the American Academy of Dermatology Summer Meeting. July 25–29, 2003; Chicago, Illinois. Poster #42.Google Scholar
  7. 7.
    Lebwohl M. Psoriasis. Lancet 2003; 361:1197–1204PubMedCrossRefGoogle Scholar
  8. 8.
    Menter A, Craig LL, Sterry W, et al. Long-term management of plaque psoriasis with continuous efalizumab therapy. J Am Acad Dermatol. In pressGoogle Scholar
  9. 9.
    Leonardi C, Menter A, Sterry W, et al. Guidelines for the long-term management of plaque psoriasis with continuous efalizumab therapy. Presented at the 3rd European Academy of Dermatology and Venereology Spring Symposium. May 19–22, 2005; Sofia, Bulgaria. Poster #32.Google Scholar
  10. 10.
    Guenther L, Langley RG, Shear NH, et al. Integrating biologic agents into management of moderate-to-severe psoriasis: A Consensus of the Canadian Psoriasis Expert Panel. J Cutan Med Surg. 2004;8(5):321–337PubMedCrossRefGoogle Scholar
  11. 11.
    Langley RG, Ho V, Lynde C, et al. Recommendations for incorporating biologicals into management of moderate-to-severe plaque psoriasis: individualized patient approaches. J Cutan Med Surg 2005; This supplementGoogle Scholar
  12. 12.
    Gottlieb AB, Gordon KB, Hamilton TK, et al. Maintenance of efficacy and safety with continuous efalizumab therapy in patients with moderate to severe chronic plaque psoriasis: final phase IIIb study results. Presented at the 63rd Annual Meeting of the American Academy of Dermatology. February 18–22, 2005; New Orleans, LA. Poster #4.Google Scholar
  13. 13.
    Poulin Y, Papp KA, Carey W, Gulliver W. Efalizumab for long-term control of moderate-to-severe psoriasis. J Cutan Med Surg 2005; This supplementGoogle Scholar
  14. 14.
    Raptiva® (efalizumab) US Prescribing Information. Genentech, Inc. 2004Google Scholar
  15. 15.
    Papp KA and Toth DP. Safety and efficacy of efalizumab retreatment: Final results from an open-label study in psoriasis. Presented at the13th Congress of the European Academy of Dermatology and Venereology. November 17–21, 2004; Florence, Italy. Poster #74.Google Scholar
  16. 16.
    Gordon K, Koo J, Feldman SR, et al. Definitions of measures of effect duration for psoriasis treatments. Psoriasis Forum 2002; 8:1–5Google Scholar
  17. 17.
    Papp K, Sobell J, Toth D, et al. Safety of subcutaneous efalizumab therapy in patients with moderate to severe plaque psoriasis. Presented at the American Academy of Dermatology Summer Meeting. July 25–29, 2003; Chicago, Ill. Poster #41.Google Scholar
  18. 18.
    Carey W, Glazer S, Gottlieb AB, et al. Relapse, rebound, and psoriasis adverse events: An Advisory Group Report. J Am Acad Dermatol In press 2005.Google Scholar
  19. 19.
    Serono International SA, Data on file, April 2005Google Scholar
  20. 20.
    Paul CF, Ho VC, McGeown C, et al. Risk of malignancies in psoriasis patients treated with cyclosporine: a 5 y cohort study. Invest Dermatol 2003; 120:211–216CrossRefGoogle Scholar
  21. 21.
    McClure SL, Valentine J, Gordon KB. Comparative tolerability of systemic treatments for plaque-type psoriasis. Drug Safety 2002; 25:913–927PubMedCrossRefGoogle Scholar
  22. 22.
    Gordon KB, Feldman SR, Koo JY, et al. Definitions of measures of effect duration for psoriasis treatments. Arch Dermatol. 2005 Jan;141(1):82–4Google Scholar
  23. 23.
    Menter A, Kardatzke D, Rundle AC, et al. Incidence and prevention of rebound upon efalizumab discontinuation. Poster presentation at the 11th International Psoriasis Symposium. June 15–18, 2005; Toronto, CanadaGoogle Scholar
  24. 24.
    Maryles S, Rozenblit M, Lebwohl M. Transition from methotrexate and cyclosporine to other therapies including retinoids, ultraviolet light and biologic agents in the management of patients with psoriasis. J Dermatolog Treat 2003; 14 (Suppl 2):7–16PubMedCrossRefGoogle Scholar
  25. 25.
    Koo JY. Current consensus and update on psoriasis therapy: a perspective from the US. J Dermatol 1999;26:723–733PubMedGoogle Scholar
  26. 26.
    Weinstein GD, White GM. An approach to the treatment of moderate to severe psoriasis with rotational therapy. J Am Acad Dermatol 1993; 28:454–459PubMedCrossRefGoogle Scholar
  27. 27.
    Carey W, Rundle AC, Kwon P, Leonardi CL. Taper regimens in the management of patients discontinuing efalizumab therapy. Presented at the 10th Annual International Psoriasis Symposium. June 14–19, 2004; Toronto, Canada. Poster #29.Google Scholar
  28. 28.
    Raptiva® (efalizumab) Canadian Product Monograph. Serono Canada, Inc. 2005Google Scholar

Copyright information

© Springer Science+Business Media, Inc. 2006

Authors and Affiliations

  • Kim A. Papp
    • 1
    Email author
  • Vincent Ho
    • 2
  • Richard Langley
    • 3
  • Charles Lynde
    • 4
  • Yves Poulin
    • 5
  • Neil Shear
    • 6
  • John Toole
    • 7
  • Catherine Zip
    • 8
  1. 1.Probity Medical ResearchWaterloo
  2. 2.University of British ColumbiaVancouver
  3. 3.Dalhousie University Queen Elizabeth II Health Science CentreHalifax
  4. 4.University of Toronto, University Health Network, and Lynde Centre for DermatologyMarkham
  5. 5.Laval University and Centre DermatologiqueSainte Foy
  6. 6.Sunnybrook & Women’s College, University of Toronto Medical School and Ventana Clinical Research Corp.Toronto
  7. 7.University of Manitoba, Dermadvances Research WinnipegWinnipeg
  8. 8.University of Calgary and The Dermatology CentreCalgary

Personalised recommendations